Jyong Biotech LtdMENS
Price$2.18

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$4.7MTTM through 31 Dec 2025
Free Cash Flow -$3MTTM through 31 Dec 2025

Margins

Current

Returns

18.8%ROE
-22.5%ROA

Balance Sheet Health

Debt / Equity-0.74x
Current Ratio0.45x
Net Debt$17.4M
Cash & Equivalents$1.2M

Quality Metrics

Altman Z-Score-1.69
Piotroski F-Score3 / 9

Multi-Year Trend

Diluted EPS-$0.06TTM
'23'24'25
FY2025: $-0.06

Dividend

No dividend

Capital Allocation

R&D Spend$813K

Segment Performance

SegmentRevenueYoYOutlook
Research and Development of Novel Therapeutics$0
View details

The company operates as a single segment focused on the development and commercialization of plant-derived therapeutics.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.